AI Earnings Predictions for Medpace Holdings Inc. (MEDP)

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1785191224.3ec31121

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

EX-99.1

2 medp-20260422exx991.htm

EX-99.1

Document

Exhibit 99.1

Investor Contact:

Lauren Morris

283-227-6409

l.morris@medpace.com

FOR IMMEDIATE RELEASE

Media Contact:

Michael Maley

283-227-6367

m.maley@medpace.com

Medpace Holdings, Inc. Reports First Quarter 2026 Results

•Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%.

•Net new business awards were $618.4 million in the first quarter of 2026, representing an increase of 23.7% from net new business awards of $500.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.88x.

•First quarter of 2026 GAAP net income was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 17.5% and 20.5% for the first quarter of 2026 and 2025, respectively.

•EBITDA was $149.4 million for the first quarter of 2026, an increase of 25.9% from EBITDA of $118.6 million for the comparable prior-year period, resulting in an EBITDA margin of 21.1%.

CINCINNATI, OHIO, April 22, 2026-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Results

Revenue for the three months ended March 31, 2026 increased 26.5% to $706.6 million, compared to $558.6 million for the comparable prior-year period. On a constant currency basis, revenue for the first quarter of 2026 increased 25.8% compared to the first quarter of 2025.

Backlog as of March 31, 2026 increased 2.9% to $2,929.2 million from $2,846.0 million as of March 31, 2025. Net new business awards were $618.4 million, representing a net book-to-bill ratio of 0.88x for the first quarter of 2026, as compared to $500.0 million for the comparable prior-year period. The Company calculates the net book-to-bill ratio by dividing net new business awards by revenue.

For the first quarter of 2026, total direct costs were $510.3 million, compared to total direct costs of $380.2 million in the first quarter of 2025. Selling, general and administrative (SG&A) expenses were $47.9 million in the first quarter of 2026, compared to SG&A expenses of $57.9 million in the first quarter of 2025.

GAAP net income for the first quarter of 2026 was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the first quarter of 2025. This resulted in a net income margin of 17.5% and 20.5% for the first quarter of 2026 and 2025, respectively.

EBITDA for the first quarter of 2026 increased 25.9% to $149.4 million, or 21.1% of revenue, compared to $118.6 million, or 21.2% of revenue, for the comparable prior-year period. On a constant currency basis, EBITDA for the first quarter of 2026 increased 28.6% from the first quarter of 2025.

A reconciliation of the Company’s non-GAAP financial measures, including EBITDA and EBITDA margin to the corresponding GAAP measures is provided below.

1

Balance Sheet and Liquidity

The Company’s Cash and cash equivalents were $652.7 million at March 31, 2026, and the Company generated $151.8 million in cash flow from operating activities during the first quarter of 2026.

2026 Financial Guidance

The Company forecasts 2026 revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Additionally, full year 2026 EBITDA is expected in the range of $605.0 million to $635.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding. This guidance does not include the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after March 31, 2026.

Leadership Update

On April 21, 2026, Jesse Geiger notified the Company of his intent to resign as President and that he will retire from the Company effective May 31, 2026. This departure is not the result of any disagreement with the Company regarding its operations, policies, or practices. Effective on Mr. Geiger’s resignation date, the Company’s Chief Executive Officer, August Troendle, will reassume the role of President until such time as the Company appoints a successor.

Conference Call Details

Medpace will host a conference call at 9:00 a.m. ET, Thursday, April 23, 2026, to discuss its first quarter 2026 results.

To participate in the confere

medp-20260209FALSE000166839700016683972026-02-092026-02-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2026

Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter)

Delaware001-3785632-0434904 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)

5375 Medpace Way Cincinnati, Ohio 45227 (Address of Principal Executive Offices)(Zip Code)

Registrant’s Telephone Number, Including Area Code: 513 579-9911 Not Applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock $0.01 par valueMEDPNASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition. On February 9, 2026, Medpace Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025. The full text of the press release was posted on the Company’s internet website and is furnished as Exhibit 99.1 hereto and incorporated herein by reference. Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, Item 2.02, including the press release attached as Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits. (d) Exhibits

Exhibit No.Description 99.1Press release dated February 9, 2026

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MEDPACE HOLDINGS, INC.

Date:February 9, 2026By:/s/ Kevin M. Brady Kevin M. Brady, Chief Financial Officer